Objetivo The SENCELL Glucose Monitoring System includes an osmotic pressure sensor, transmitter and mobile medical application. The miniaturized sensor is designed to be implanted into the subcutaneous space of arm wrist or other suitable body sites and requires no battery or wires for the sensor operation and for communication with the transmitter. After insertion, the sensor is designed to function noninvasively, automatically, and continuously for a long term duration that is comparable or longer than existing product alternatives.The miniaturized SENCELL is designed to continuously measure glucose in the interstitial fluid for a long term duration that is comparable or longer than existing product alternatives. Unlike currently used glucose sensors, the Sencell is intended to be implanted subcutaneously on the arm wrist or other subcutaneous places in the body with no sensor part protruding from the skin. Encased in a biocompatible material, the device utilizes a unique osmotic pressure assessment technology, which translates the signal of a physical miniaturized osmotic pressure cell into an accurate glucose reading that can be used for determination of insulin doses and to generate warning signals in case of hypoglycemia or hyperglycemia development. The inner core of the device is the unique and proprietary osmotic patented pressure cell, which is covered on one side by a semi-permeable membrane. The membrane is enclosed inside the top of a cavity where the pressure transducer is also located. The cavity contains Concanavalin A and Dextran.The use of ConA/Dextran as enzymatic component significantly improves the sensitivity to changes in the blood sugar level while reducing the influence from other substances in the blood. In the final product, the measurement is then relayed to the transmitter. The entire measurement is designed to be done autonomously and independently without any prompting by the user. However, the user can induce a measurement at any time Ámbito científico medical and health sciencesclinical medicineendocrinologydiabetesengineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technologybluetoothengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2016-2017 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador LIFECARE AS Aportación neta de la UEn € 50 000,00 Dirección YTREBYGDSVEGEN 215 5258 Bergen Noruega Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Norge Vestlandet Vestland Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
